Skip to content

AptarGroup ATR Additional Paid-In Capital

Additional Paid-In Capital at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$0-100%
Amcor logo
AmcorAMCR
$12.25B+202%
Nordson logo
NordsonNDSN
$790.13M+8.9%
Baxter International logo
Baxter InternationalBAX
$6.21B-1.5%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$27.39M+261%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$1.96B+4.5%

Other financials

Income statement

See full
Revenue$982.9M+10.8%
Gross profit$351.9M+4.6%
Operating income$107.5M-5.2%
Net income$72.7M-7.8%
EPS (diluted)$1.12-4.3%

Balance sheet

See full
Cash & equivalents$225.0M+78.8%
Total debt$1.4B+32.7%
Total equity$2.6B+3.6%
Total assets$5.1B+12.6%

Cash flow

See full
Operating cash flow$118.7M+43.5%
CapEx$65.4M+15.0%
Free cash flow$53.3M+106%

Valuation

See full
Market cap$7.68B-17.9%
Enterprise value$8.89B-13.9%
P/E19.9×-5.4×
P/S-0.6×

Profitability

See full
Gross margin36.7%-1.6pp
Operating margin12.8%-1.2pp
Net margin10%-0.4pp
FCF margin8.4%-2.1pp

Returns & leverage

See full
Return on equity15%-0.2pp
Debt / equity0.5×+0.1×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: AptarGroup’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about AptarGroup's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AptarGroup's additional paid-in capital?
AptarGroup (ATR) reported additional paid-in capital of $1.19B in Q1 2026.
How has AptarGroup's additional paid-in capital changed year-over-year?
AptarGroup's additional paid-in capital increased by 4.4% year-over-year, from $1.14B to $1.19B.
What is the long-term trend for AptarGroup's additional paid-in capital?
Over 5 years (2020 to 2025), AptarGroup's additional paid-in capital has grown at a 6.5% compound annual growth rate (CAGR), from $849.16M to $1.17B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.